T1	PrimaryOutcome 38 58	viral clearance rate
T2	TimeFrame 59 87	at day 7 after randomization
R1	MeasuredAt Arg1:T1 Arg2:T2	
T3	OutcomeDefinition 214 359	reverse transcriptase polymerase chain reaction (RT-PCR) negative on at least 2 consecutive oropharyngeal swabs collected at least 1â€“2 days apart
R2	DefinedAs Arg1:T1 Arg2:T3	
T4	SecondaryOutcome 391 406	viral clearance
T5	TimeFrame 407 425	at day 3 and day 5
R3	MeasuredAt Arg1:T4 Arg2:T5	
T6	PrimaryOutcome 431 464	critical illness rate of subjects
T7	TimeFrame 465 503	during the 14 days after randomization
R4	MeasuredAt Arg1:T6 Arg2:T7	
T8	SecondaryOutcome 505 535	the mortality rate of subjects
T9	TimeFrame 536 545	at day 14
R5	MeasuredAt Arg1:T8 Arg2:T9	
T10	SecondaryOutcome 551 615	the number of participants with treatment-related adverse events
